NCT04552873 (NAT-URE) is a NA clinical trial of Urea in Hyponatremia, sponsored by University Hospital, Grenoble.

Who is sponsoring NCT04552873?

NCT04552873 is sponsored by University Hospital, Grenoble.

What drugs are being tested in NCT04552873?

Interventions in NCT04552873: Urea, PLACEBO.

What condition does NCT04552873 study?

NCT04552873 studies Hyponatremia, Subarachnoid Hemorrhage, SIADH.

Is NCT04552873 still recruiting?

NCT04552873 is currently active, enrolled. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT04552873: NAT-URE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage

Active, enrolled NA Last updated 16 April 2025

What this trial tests

NA trial testing Urea in Hyponatremia in 52 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

3 December 2020

Primary endpoint
3 December 2024

1 August 2025

Quick facts

Lead sponsor	University Hospital, Grenoble
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	52
Start date	3 December 2020
Primary completion	3 December 2024
Estimated completion	1 August 2025
Sites	1 location across France

Drugs / interventions tested

Urea — full drug profile →
PLACEBO

Conditions studied

Hyponatremia — all drugs for Hyponatremia →
Subarachnoid Hemorrhage — all drugs for Subarachnoid Hemorrhage →
SIADH — all drugs for SIADH →

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Hyponatremia or Subarachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hyponatremia is defined as a plasma sodium concentration below 135 mmol / L. This is a common occurrence (20-50%) during subarachnoid hemorrhage (SAH). Its appearance is often associated with vasospasm. It is associated with an increase in morbidity and mortality linked to induced neurological disorders. Hyponatremia is caused by two etiologies: the syndrome of inappropriate secretion of anti-diuretic hormone (SIADH), and the cerebral salt wasting syndrome, CSWS. Theoretically, these two entities are differentiated by the patient's volemia; in practice, this parameter is difficult to measure. In addition, the correction of hyponatremia is diametrically opposed according to its mechanism: water restriction in the case of SIADH, sodium intake in the event of CSWS. Urea is offered as a second-line treatment in the event of treatment failure to correct hyponatremia. However, the efficacy of this treatment is based on small, observational, retrospective studies. Moreover, the mechanism of action of urea remains poorly understood: it could be a hyperosmolar effect or passive renal reabsorption of sodium.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Urea

Trials testing the same drug.

NCT05890690 — Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome · NA · completed
NCT04588207 — Urea for Chronic Hyponatremia · Phase 2 · terminated
NCT04127513 — Comparison of 12% Ammonium Lactate and 10% Urea Cream in Geriatric With Xerosis Cutis · Phase 3 · completed

Other recruiting trials for Hyponatremia

Currently open trials in the same condition.

NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting
NCT06020495 — Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia · Phase 3 · recruiting
NCT06781710 — Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Synd · recruiting
NCT07430787 — Hyponatremia - Complications, Prognosis, Epidemiology in Finnish Tertiary Care · active not recruiting
NCT06408077 — Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges · NA · recruiting

Other University Hospital, Grenoble trials

Trials by the same sponsor.

NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04552873 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04552873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing